In order to maximize the applications of these specific inhibitors, future therapeutic strategies should include the molecular pathological diagnosis of GBM patients like PIK3CA, RAS mutations and PTEN loss/mutation prior to drug administration. The gene discussed is PTEN; the disease is glioblastoma.